MX2017009247A - Un metodo para la activacion de bacterias de acido lactico. - Google Patents
Un metodo para la activacion de bacterias de acido lactico.Info
- Publication number
- MX2017009247A MX2017009247A MX2017009247A MX2017009247A MX2017009247A MX 2017009247 A MX2017009247 A MX 2017009247A MX 2017009247 A MX2017009247 A MX 2017009247A MX 2017009247 A MX2017009247 A MX 2017009247A MX 2017009247 A MX2017009247 A MX 2017009247A
- Authority
- MX
- Mexico
- Prior art keywords
- bacteria
- lactic acid
- acid bacteria
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a métodos para activar bacterias de ácido láctico vivas, los cuales comprenden exponer dichas bacterias a una preparación que comprende citrato, en donde dichas bacterias tienen la capacidad para utilizar el citrato como un aceptor de electrones externo. La presente invención se refiere además a los métodos para mejorar la actividad de ciertas bacterias vivas en los mamíferos. Más específicamente, la invención se refiere a mejorar el despertar de ciertas bacterias de ácido láctico a partir del estado secado por congelación. La presente invención también se refiere a preparaciones que comprenden estas bacterias activadas, y a los usos terapéuticos de dichas bacterias activadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103201P | 2015-01-14 | 2015-01-14 | |
| PCT/EP2016/050694 WO2016113363A1 (en) | 2015-01-14 | 2016-01-14 | A method of activating lactic acid bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017009247A true MX2017009247A (es) | 2017-10-12 |
Family
ID=55129894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009247A MX2017009247A (es) | 2015-01-14 | 2016-01-14 | Un metodo para la activacion de bacterias de acido lactico. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170304376A1 (es) |
| EP (1) | EP3244903B1 (es) |
| JP (1) | JP6837442B2 (es) |
| CN (1) | CN107427461B (es) |
| AU (1) | AU2016208007B2 (es) |
| BR (1) | BR112017014192B1 (es) |
| CA (1) | CA2972963C (es) |
| CL (1) | CL2017001722A1 (es) |
| CY (1) | CY1126127T1 (es) |
| ES (1) | ES2952585T3 (es) |
| HK (1) | HK1247561A1 (es) |
| HR (1) | HRP20230639T1 (es) |
| HU (1) | HUE062482T2 (es) |
| MX (1) | MX2017009247A (es) |
| PL (1) | PL3244903T3 (es) |
| RS (1) | RS64392B1 (es) |
| WO (1) | WO2016113363A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11357803B2 (en) | 2017-09-22 | 2022-06-14 | Iowa State University Research Foundation, Inc. | Probiotic compositions for production of dopamine |
| KR20200001543A (ko) * | 2018-06-26 | 2020-01-06 | 씨제이제일제당 (주) | 구연산염을 포함하는 유산균 동결 보호용 조성물 |
| CN110320840B (zh) * | 2019-07-11 | 2021-06-22 | 四川长虹网络科技有限责任公司 | 一种可降低物联网产品电池电量消耗的方法及系统 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3436581B2 (ja) * | 1994-03-18 | 2003-08-11 | 雪印乳業株式会社 | 乳糖分解酵素活性の高い菌体の製造法 |
| US6506413B1 (en) * | 2001-04-30 | 2003-01-14 | Joseph C. Ramaekers | Compositions for treating animal diseases and syndromes |
| US20030017192A1 (en) * | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
| JP3957132B2 (ja) * | 2001-09-07 | 2007-08-15 | キッコーマン株式会社 | 低濁性醤油乳酸菌の分離用培地、同培地を用いる低濁性醤油乳酸菌の分離法及び同乳酸菌を用いる清澄度の高い醤油の製造法 |
| FR2859217B1 (fr) * | 2003-09-03 | 2005-11-11 | Rhodia Chimie Sa | Activateur pour ferment a base de bacteries lactiques et procede de preparation d'un produit mettant en oeuvre ledit activateur |
| JP2007330157A (ja) * | 2006-06-15 | 2007-12-27 | Obihiro Univ Of Agriculture & Veterinary Medicine | 乳酸菌及び乳酸菌由来物の癌細胞増殖抑制作用および炎症性サイトカイン抑制作用を測定する方法 |
| US8617537B2 (en) * | 2008-06-10 | 2013-12-31 | Biogaia Ab | Controlled activation of the reuterin-production machinery of lactobacillus |
| FR2967070B1 (fr) * | 2010-11-05 | 2013-07-05 | Oreal | Acide gras monoinsature pour prevenir et/ou traiter les imperfections du teint de la peau |
| EP2408171A1 (en) * | 2010-07-16 | 2012-01-18 | Research In Motion Limited | Application programming interface for mapping application |
| EP2658402A1 (en) * | 2010-12-31 | 2013-11-06 | Abbott Laboratories | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
| JP5622110B2 (ja) * | 2011-02-21 | 2014-11-12 | 株式会社農 | 新規乳酸菌 |
| JP6051112B2 (ja) * | 2013-06-05 | 2016-12-27 | 公立大学法人大阪府立大学 | 白金族金属の回収方法 |
| CN104206539A (zh) * | 2014-08-14 | 2014-12-17 | 澳优乳业（中国）有限公司 | 一种益生菌婴幼儿奶粉 |
-
2016
- 2016-01-14 MX MX2017009247A patent/MX2017009247A/es unknown
- 2016-01-14 US US15/320,996 patent/US20170304376A1/en active Pending
- 2016-01-14 WO PCT/EP2016/050694 patent/WO2016113363A1/en active Application Filing
- 2016-01-14 AU AU2016208007A patent/AU2016208007B2/en active Active
- 2016-01-14 BR BR112017014192-2A patent/BR112017014192B1/pt active IP Right Grant
- 2016-01-14 HR HRP20230639TT patent/HRP20230639T1/hr unknown
- 2016-01-14 CN CN201680005682.2A patent/CN107427461B/zh active Active
- 2016-01-14 HU HUE16700501A patent/HUE062482T2/hu unknown
- 2016-01-14 PL PL16700501.6T patent/PL3244903T3/pl unknown
- 2016-01-14 RS RS20230608A patent/RS64392B1/sr unknown
- 2016-01-14 ES ES16700501T patent/ES2952585T3/es active Active
- 2016-01-14 JP JP2017555837A patent/JP6837442B2/ja active Active
- 2016-01-14 EP EP16700501.6A patent/EP3244903B1/en active Active
- 2016-01-14 CA CA2972963A patent/CA2972963C/en active Active
-
2017
- 2017-06-28 CL CL2017001722A patent/CL2017001722A1/es unknown
-
2018
- 2018-05-30 HK HK18107030.7A patent/HK1247561A1/zh unknown
-
2023
- 2023-07-11 CY CY20231100325T patent/CY1126127T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016208007B2 (en) | 2021-09-09 |
| CN107427461B (zh) | 2021-04-13 |
| CL2017001722A1 (es) | 2018-04-06 |
| BR112017014192A2 (pt) | 2018-03-06 |
| JP2018503684A (ja) | 2018-02-08 |
| CA2972963C (en) | 2023-03-14 |
| HK1247561A1 (zh) | 2018-09-28 |
| BR112017014192B1 (pt) | 2022-02-01 |
| JP6837442B2 (ja) | 2021-03-03 |
| EP3244903A1 (en) | 2017-11-22 |
| CA2972963A1 (en) | 2016-07-21 |
| AU2016208007A1 (en) | 2017-07-06 |
| US20170304376A1 (en) | 2017-10-26 |
| PL3244903T3 (pl) | 2023-08-14 |
| ES2952585T3 (es) | 2023-11-02 |
| HUE062482T2 (hu) | 2023-11-28 |
| RS64392B1 (sr) | 2023-08-31 |
| HRP20230639T1 (hr) | 2023-09-29 |
| CY1126127T1 (el) | 2023-11-15 |
| EP3244903C0 (en) | 2023-06-07 |
| WO2016113363A1 (en) | 2016-07-21 |
| CN107427461A (zh) | 2017-12-01 |
| EP3244903B1 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
| WO2016210384A3 (en) | Bacteria engineered to treat metabolic diseases | |
| MX2021001169A (es) | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas. | |
| CA2900779C (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
| WO2016200614A3 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| PH12015501887A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| WO2017139697A8 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| PH12018501072A1 (en) | Modified release orally administered amino acid formulations | |
| PH12015501888A1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
| MX2017000775A (es) | Vacunas de meningococos. | |
| MX370628B (es) | Composiciones y metodos para tratar las espinillas. | |
| PH12016502002B1 (en) | Novel bacteriophage and composition comprising same | |
| MX2019005097A (es) | Composiciones y metodos para tratar la enfermedad del enverdecimiento de los citricos. | |
| GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| NZ741342A (en) | Daptomycin formulations and uses thereof | |
| CY1126127T1 (el) | Παρασκευασμα που περιεχει γαλακτοβακιλλους reuteri και κιτρικο οξυ για ιατρικη χρηση | |
| PH12019501439A1 (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof | |
| TR201907274T4 (tr) | Kurutulmuş Biyoselüloz Üretimi İçin Yöntem. | |
| WO2017123610A3 (en) | Bacteria engineered to detoxify deleterious molecules | |
| WO2013162981A3 (en) | Breast implant spacers for the treatment of periprosthetic breast implant infections | |
| EA201590796A1 (ru) | Фибринолитические композиции, включающие бромелаин и наттокиназу, для предотвращения и лечения флеботромботических состояний | |
| MX2017007969A (es) | Bacterias de acido lactico y su uso para el tratamiento de mastitis. | |
| EP2579863A4 (en) | COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS |